

Contact

Merck KGaA, Darmstadt, Germany
Investor Relations
Frankfurter Strasse 250
64293 Darmstadt
Germany
Phone: +49 6151 72 3321
e-mail: investor.relations@merckgroup.com
www.merckgroup.com

WKN: 659990
ISIN: DE0006599905
Ticker Symbol: MRK

Financial Statements Q1 2022 – Q2 2023

Content

1 Income statements

- 1.1 Group, quarterly
- 1.2 Life Science, quarterly
- 1.3 Healthcare, quarterly
- 1.4 Electronics, quarterly
- 1.5 Corporate/Others, quarterly
- 1.6 Financial result, quarterly

2 Cash flow statement**3 Balance sheet**

Income Statement Merck KGaA, Darmstadt, Germany

Group € million	2022								2023								Change YoY								
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	
Net sales	5,197.8	5,568.4	10,766.2	5,805.7	16,571.9	5,660.4	11,466.1	22,232.3	5,293.0	5,302.4	10,595.3								1.8%	-4.8%	-1.6%				
Cost of sales	-1,987.0	-2,108.6	-4,095.6	-2,147.5	-6,243.1	-2,284.2	-4,431.6	-8,527.3	-1,972.5	-2,138.9	-4,111.4								-0.7%	1.4%	0.4%				
thereof amortization of intangible assets	-50.3	-53.2	-103.6	-52.3	-155.9	-51.3	-103.6	-207.1	-48.2	-46.2	-94.3								-4.3%	-13.3%	-8.9%				
Gross profit	3,210.8	3,459.8	6,670.5	3,658.2	10,328.8	3,376.2	7,034.4	13,705.0	3,320.4	3,163.5	6,483.9								3.4%	-8.6%	-2.8%				
<i>in % of net sales</i>	61.8%	62.1%	62.0%	63.0%	62.3%	59.6%	61.4%	61.6%	62.7%	59.7%	61.2%														
SG&A	-1,451.8	-1,683.1	-3,135.0	-1,782.4	-4,917.3	-1,793.0	-3,575.3	-6,710.3	-1,688.2	-1,593.6	-3,281.8								16.3%	-5.3%	4.7%				
<i>in % of net sales</i>	27.9%	30.2%	29.1%	30.7%	29.7%	31.7%	31.2%	30.2%	31.9%	30.1%	31.0%														
Marketing and selling expenses	-1,087.2	-1,193.6	-2,280.8	-1,223.5	-3,504.3	-1,209.4	-2,432.9	-4,713.7	-1,109.1	-1,139.4	-2,248.5								2.0%	-4.5%	-1.4%				
thereof amortization of intangible assets (M&S)	-144.8	-153.7	-298.5	-159.9	-458.4	-158.1	-317.9	-616.4	-151.3	-148.9	-300.2								4.5%	-3.1%	0.6%				
Administration expenses	-287.2	-330.5	-617.7	-327.9	-945.7	-360.8	-688.7	-1,306.4	-357.9	-345.0	-702.9								24.6%	4.4%	13.8%				
Impairment losses and reversals (IFRS 9)	-5.0	-8.7	-13.6	6.2	-7.4	1.9	8.1	-5.5	-2.2	-9.7	-11.9								-56.3%	12.3%	-12.7%				
Other operating expenses/income	-72.4	-150.4	-222.8	-237.2	-460.0	-224.6	-461.8	-684.6	-219.0	-99.4	-318.4								202.3%	-33.9%	42.9%				
Impairments**	-2.6	-90.0	-92.6	-10.9	-103.5	-128.4	-139.3	-231.9	-9.7	-36.9	-46.6								271.0%	-59.0%	-49.7%				
Research and development costs	-585.5	-599.6	-1,185.1	-641.7	-1,826.8	-693.7	-1,335.4	-2,520.5	-597.3	-600.4	-1,197.7								2.0%	0.1%	1.1%				
<i>in % of net sales</i>	11.3%	10.8%	11.0%	11.1%	11.0%	12.3%	11.6%	11.3%	11.3%	11.3%	11.3%														
thereof amortization of intangible assets (R&D)	-1.7	-1.7	-3.4	-1.6	-5.0	-1.7	-3.3	-6.7	-4.4	-3.0	-7.4								165.5%	75.1%	119.5%				
EBIT	1,173.4	1,177.0	2,350.4	1,234.2	3,584.6	889.6	2,123.7	4,474.2	1,035.0	969.5	2,004.4								-11.8%	-17.6%	-14.7%				
<i>in % of net sales</i>	22.6%	21.1%	21.8%	21.3%	21.6%	15.7%	18.5%	20.1%	19.6%	18.3%	18.9%														
Depreciation and amortization	429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1	455.5	482.3	937.8								6.0%	-9.4%	-2.5%				
EBITDA	1,603.0	1,709.4	3,312.3	1,703.9	5,016.2	1,488.1	3,191.9	6,504.3	1,490.5	1,451.8	2,942.3								-7.0%	-15.1%	-11.2%				
<i>in % of net sales</i>	30.8%	30.7%	30.8%	29.3%	30.3%	26.3%	27.8%	29.3%	28.2%	27.4%	27.8%														
EBITDA pre	1,628.8	1,782.0	3,410.8	1,810.5	5,221.3	1,627.9	3,438.4	6,849.2	1,587.0	1,553.3	3,140.3								-2.6%	-12.8%	-7.9%				
<i>in % of net sales</i>	31.3%	32.0%	31.7%	31.2%	31.5%	28.8%	30.0%	30.8%	30.0%	29.3%	29.6%														
Financial result	-34.3	-55.1	-89.4	-47.0	-136.4	-50.5	-97.5	-186.9	-22.7	-75.7	-98.4								-33.9%	37.4%	10.0%				
Profit before income tax from continuing operations	1,139.1	1,122.0	2,261.0	1,187.2	3,448.2	839.1	2,026.2	4,287.3	1,012.3	893.8	1,906.1								-11.1%	-20.3%	-15.7%				
Income tax	-255.4	-251.7	-507.1	-261.2	-768.3	-179.7	-440.9	-948.0	-212.6	-187.7	-400.3								-16.8%	-25.4%	-21.1%				
<i>Income tax rate</i>	22.4%	22.4%	22.4%	22.0%	22.3%	21.4%	21.8%	22.1%	21.0%	21.0%	21.0%														
Profit after tax from continuing operations	883.7	870.2	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3	799.7	706.1	1,505.8								-9.5%	-18.9%	-14.1%				
Profit after tax from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								n.m.	n.m.	n.m.				
Profit after tax	883.7	870.2	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3	799.7	706.1	1,505.8								-9.5%	-18.9%	-14.1%				
of which: attributable to Merck KGaA shareholders (n of which: attributable to non-controlling interests)	880.4	867.1	1,747.5	923.2	2,670.7	655.0	1,578.1	3,325.7	796.2	703.6	1,499.8								-9.6%	-18.9%	-14.2%				
	3.3	3.1	6.4	2.8	9.2	4.4	7.2	13.6	3.5	2.5	6.0								6.3%	-19.2%	-6.1%				
EPS in €	2.02	1.99	4.02	2.12	6.14	1.51	3.63	7.65	1.83	1.62	3.45								-9.4%	-18.6%	-14.2%				
thereof from continuing operations	2.02	1.99	4.02	2.12	6.14	1.51	3.63	7.7	1.83	1.62	3.45								-9.4%	-18.6%	-14.2%				
thereof from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.0	0.00	0.00	0.00								n.m.	n.m.	n.m.				
EPS pre in €*	2.41	2.64	5.05	2.68	7.73	2.32	5.01	10.05	2.36	2.20	4.57								-2.1%	-16.7%	-9.5%				
Number of theoretical shares in million	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8														
Reconciliation to EBITDA pre																									
EBITDA	1,603.0	1,709.4	3,312.3	1,703.9	5,016.2	1,488.1	3,191.9	6,504.3	1,490.5	1,451.8	2,942.3								-7.0%	-15.1%	-11.2%				
Adjustments																									
thereof: Cost of Sales	1.6	7.8	9.4	6.0	15.4	16.2	22.2	31.6	2.7	4.6	7.2								69.6%	-41.6%	-23.0%				
thereof: Marketing and selling expenses	0.5	14.0	14.6	6.4	21.0	11.3	17.7	32.3	-0.9	5.4	4.5								n.m.	-61.9%	-69.2%				
thereof: Administration expenses	19.6	29.7	49.3	31.4	80.7	34.4	65.7	115.1	71.7	41.9	113.6								264.8%	41.3%	130.3%				
thereof: Other operating expenses/income	3.0	14.8	17.7	40.7	58.5	33.0	73.7	91.4	30.9	42.1	73.0								>1,000%	184.9%	311.5%				
thereof: Research and development	1.1	6.3	7.4	22.1	29.5	45.0	67.1	74.5	-7.9	7.6	-0.3								n.m.	19.4%	n.m.				
Total	25.8	72.6	98.4	106.6	205.0	139.8	246.4	344.9	96.5	101.5	198.0								274.1%	39.7%	101.1%				
EBITDA pre	1,628.8	1,782.0	3,410.8	1,810.5	5,221.3	1,627.9	3,438.4	6,849.2	1,587.0	1,553.3	3,140.3								-2.6%	-12.8%	-7.9%				

Due to rounding the sum of individual values may not add up to totals presented.

* For continuing operations.

** Only reflects impairments classified as adjustments.

Reconciliation to EBITDA, EBITDA pre and EPS pre
Group

€ million

	2022								2023								Change YoY								
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	
a) Reconciliation to EBITDA and EBITDA pre																									
EBITDA																									
EBIT	1,173.4	1,177.0	2,350.4	1,234.2	3,584.6	889.6	2,123.7	4,474.2	1,035.0	969.5	2,004.4							-11.8%	-17.6%	-14.7%					
Depreciation and amortization	429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1	455.5	482.3	937.8							6.0%	-9.4%	-2.5%					
Regular depreciation and amortization*	230.2	233.7	463.9	245.0	708.9	258.9	503.9	967.8	242.0	243.2	485.2							5.1%	4.0%	4.6%					
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0	4.2	4.2							n.m.	n.m.	>1.000%					
Amortization of purchased intangible assets	196.8	208.7	405.4	213.8	619.2	211.0	424.8	830.2	203.8	198.1	401.9							3.6%	-5.1%	-0.9%					
Impairments (net)**	2.6	90.0	92.6	10.9	103.5	128.4	139.3	231.9	9.7	36.9	46.6							271.0%	-59.0%	-49.7%					
Total	1,603.0	1,709.4	3,312.3	1,703.9	5,016.2	1,488.1	3,191.9	6,504.3	1,490.5	1,451.8	2,942.3							-7.0%	-15.1%	-11.2%					
Adjustments																									
Acquisition costs	1.5	8.6	10.1	7.3	17.4	11.6	18.8	28.9	9.2	4.8	14.0							494.7%	-43.8%	38.6%					
Restructuring costs	8.3	37.8	46.1	63.1	109.2	89.2	152.3	198.4	44.3	39.3	83.6							431.4%	4.1%	81.3%					
Integration costs/IT costs	20.0	24.2	44.1	22.7	66.9	20.7	43.4	87.5	23.5	27.1	50.6							17.7%	12.0%	14.5%					
Gain (-)/ losses (+) on the divestment of businesses	-10.3	-21.6	-31.9	-4.1	-36.0	-1.5	-5.6	-37.5	0.3	17.1	17.4							n.m.	n.m.	n.m.					
Other one-time costs	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2	13.2	32.4							208.4%	-44.5%	8.0%					
Total	25.8	72.6	98.4	106.6	205.0	139.8	246.4	344.9	96.5	101.5	198.0							274.1%	39.7%	101.1%					
EBITDA pre	1,628.8	1,782.0	3,410.8	1,810.5	5,221.3	1,627.9	3,438.4	6,849.2	1,587.0	1,553.3	3,140.3							-2.6%	-12.8%	-7.9%					
b) Reconciliation to EPS pre																									
1) Reconciliation starting from EBITDA pre																									
EBITDA pre	1,628.8	1,782.0	3,410.8	1,810.5	5,221.3	1,627.9	3,438.4	6,849.2	1,587.0	1,553.3	3,140.3							-2.6%	-12.8%	-7.9%					
Regular depreciation and amortization*	-230.2	-233.7	-463.9	-245.0	-708.9	-258.9	-503.9	-967.8	-242.0	-243.2	-485.2							5.1%	4.0%	4.6%					
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	-0.2	-0.2	-0.2	0.0	-4.2	-4.2							n.m.	n.m.	>1.000%					
Financial result	-34.3	-55.1	-89.4	-47.0	-136.4	-50.5	-97.5	-186.9	-22.7	-75.7	-98.4							-33.9%	37.4%	10.0%					
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0														
Profit before income tax pre	1,364.3	1,493.2	2,857.5	1,518.5	4,375.9	1,318.3	2,836.8	5,694.2	1,322.3	1,230.2	2,552.5							-3.1%	-17.6%	-10.7%					
Income tax pre	-313.8	-343.4	-657.2	-349.2	-1,006.5	-303.2	-652.5	-1,309.7	-290.9	-270.6	-561.6							-7.3%	-21.2%	-14.6%					
<i>underlying tax rate</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>22.0%</i>	<i>22.0%</i>	<i>22.0%</i>														
Non-controlling interest	-3.3	-3.1	-6.4	-2.8	-9.2	-4.4	-7.2	-13.6	-3.5	-2.5	-6.0							6.3%	-19.2%	-6.1%					
Net income pre	1,047.2	1,146.7	2,193.8	1,166.4	3,360.3	1,010.7	2,177.1	4,371.0	1,027.9	957.1	1,984.9							-1.8%	-16.5%	-9.5%					
EPS pre in €**	2.41	2.64	5.05	2.68	7.73	2.32	5.01	10.05	2.36	2.20	4.57							-2.1%	-16.7%	-9.5%					
2) Reconciliation starting from Profit before tax																									
Profit before income tax	1,139.1	1,122.0	2,261.0	1,187.2	3,448.2	839.1	2,026.2	4,287.3	1,012.3	893.8	1,906.1							-11.1%	-20.3%	-15.7%					
Amortization of purchased intangible assets	196.8	208.7	405.4	213.8	619.2	211.0	424.8	830.2	203.8	198.1	401.9							3.6%	-5.1%	-0.9%					
Impairments**	2.6	90.0	92.6	10.9	103.5	128.4	139.3	231.9	9.7	36.9	46.6							271.0%	-59.0%	-49.7%					
Adjustments																									
Acquisition costs	1.5	8.6	10.1	7.3	17.4	11.6	18.8	28.9	9.2	4.8	14.0							494.7%	-43.8%	38.6%					
Restructuring costs	8.3	37.8	46.1	63.1	109.2	89.2	152.3	198.4	44.3	39.3	83.6							431.4%	4.1%	81.3%					
Integration costs/IT costs	20.0	24.2	44.1	22.7	66.9	20.7	43.4	87.5	23.5	27.1	50.6							17.7%	12.0%	14.5%					
Gain (-)/ losses (+) on the divestment of businesses	-10.3	-21.6	-31.9	-4.1	-36.0	-1.5	-5.6	-37.5	0.3	17.1	17.4							n.m.	n.m.	n.m.					
Other one-time costs	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2	13.2	32.4							208.4%	-44.5%	8.0%					
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0														
Total adjustments	25.8	72.6	98.4	106.6	205.0	139.8	246.4	344.9	96.5	101.5	198.0							274.1%	39.7%	101.1%					
Profit before income tax pre	1,364.3	1,493.2	2,857.5	1,518.5	4,375.9	1,318.3	2,836.8	5,694.2	1,322.3	1,230.2	2,552.5							-3.1%	-17.6%	-10.7%					
Income tax pre	-313.8	-343.4	-657.2	-349.2	-1,006.5	-303.2	-652.5	-1,309.7	-290.9	-270.6	-561.6							-7.3%	-21.2%	-14.6%					
<i>underlying tax rate</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>23.0%</i>	<i>22.0%</i>	<i>22.0%</i>	<i>22.0%</i>														
Total costs excluded from Net income	166.8	279.5	446.3	243.2	689.5	355.7	599.0	1,045.3	231.7	253.5	485.2							38.9%	-9.3%	8.7%					
Total costs excluded from EPS in €	0.38	0.64	1.03	0.56	1.59	0.82	1.38	2.40	0.53	0.58	1.12							39.5%	-9.4%	8.7%					
Non-controlling interest	-3.3	-3.1	-6.4	-2.8	-9.2	-4.4	-7.2	-13.6	-3.5	-2.5	-6.0							6.3%	-19.2%	-6.1%					
Net income pre	1,047.2	1,146.7	2,193.8	1,166.4	3,360.2	1,010.7	2,177.1	4,371.0	1,027.9	957.1	1,984.9							-1.8%	-16.5%	-9.5%					
EPS pre in €***	2.41	2.64	5.05	2.68	7.73	2.32	5.01	10.05	2.36	2.20	4.57							-2.1%	-16.7%	-9.5%					

Number of theoretical shares in million

434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8
-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** Only reflects impairments classified as adjustments.

*** For continuing operations.

Breakdown of depreciation and amortization and adjustments

Group € million	Division	2022									2023									Change YoY						
		Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	
a) Depreciation and amortization																										
Regular depreciation and amortization*		all	230.2	233.7	463.9	245.0	708.9	258.9	503.9	967.8	242.0	243.2	485.2				5.1%	4.0%	4.6%							
Impairments not adjusted		all	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0	4.2	4.2				n.m.	n.m.	>1.000%							
Amortization of purchased intangible assets																										
Life Science	LS	109.9	121.1	231.0	123.5	354.4	123.5	246.9	477.9	118.2	115.8	234.0				7.5%	-4.3%	1.3%								
Healthcare	HC	1.4	1.3	2.8	1.3	4.0	0.3	1.5	4.3	1.5	1.6	3.2				8.5%	20.9%	14.5%								
Electronics	EL	85.4	86.3	171.7	89.0	260.7	87.3	176.3	348.0	84.1	80.6	164.7				-1.6%	-6.5%	-4.1%								
Total		196.8	208.7	405.4	213.8	619.2	211.0	424.8	830.2	203.8	198.1	401.9				3.6%	-5.1%	-0.9%								
Impairments (net)**		all	2.6	90.0	92.6	10.9	103.5	128.4	139.3	231.9	9.7	36.9	46.6				271.0%	-59.0%	-49.7%							
Total depreciation and amortization			429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1	455.5	482.3	937.8				6.0%	-9.4%	-2.5%							
b) Adjustments																										
Acquisition costs			1.5	8.6	10.1	7.3	17.4	11.6	18.8	28.9	9.2	4.8	14.0				494.7%	-43.8%	38.6%							
Restructuring costs																										
Life Science	LS	-3.1	13.1	10.0	28.3	38.2	2.3	30.6	40.6	0.4	1.8	2.2				n.m.	-85.9%	-77.5%								
Healthcare	HC	1.9	8.3	10.2	24.5	34.7	56.3	80.7	91.0	-7.3	12.0	4.7				n.m.	44.8%	-54.0%								
Electronics	EL	4.7	8.5	13.1	3.4	16.6	14.0	17.4	30.6	2.2	6.9	9.1				-53.7%	-18.4%	-30.9%								
Corporate and Other	CO	4.8	7.9	12.8	7.0	19.8	16.5	23.5	36.3	49.0	18.5	67.6				>1.000%	133.6%	429.4%								
Total		8.3	37.8	46.1	63.1	109.2	89.2	152.3	198.4	44.3	39.3	83.6				431.4%	4.1%	81.3%								
Integration costs/IT costs																										
Integration Cost	LS/EL/CO	5.0	2.2	7.1	-2.1	5.0	4.2	2.1	9.2	1.9	2.0	4.0				-61.2%	-5.1%	-44.2%								
ERP/HR systems	all	15.0	22.0	37.0	24.8	61.9	16.4	41.3	78.3	21.6	25.0	46.6				43.7%	13.6%	25.8%								
Total		20.0	24.2	44.1	22.7	66.9	20.7	43.4	87.5	23.5	27.1	50.6				17.7%	12.0%	14.5%								
Gain (-)/ losses (+) on the divestment of businesses																										
Costs related to former business activities	CO	-10.3	-11.5	-21.8	-4.1	-25.9	3.2	-0.9	-22.7	0.0	21.0	21.0				-100.0%	n.m.	n.m.								
Costs related to former business activities	EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.								
Sale of CH, Allergopharma and others	HC	0.0	-10.1	-10.1	0.0	-10.1	-4.7	-4.7	-14.8	0.3	-3.9	-3.6				n.m.	-61.5%	-64.5%								
Costs related to former business activities	LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.								
Total		-10.3	-21.6	-31.9	-4.1	-36.0	-1.5	-5.6	-37.5	0.3	17.1	17.4				n.m.	n.m.	n.m.								
Other one-time costs																										
Others	HC	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				-100.0%	n.m.	-100.0%								
	LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.								
	EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				n.m.	n.m.	n.m.								
	CO	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2	13.2	32.4				208.4%	-44.5%	8.0%								
Total		6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2	13.2	32.4				208.4%	-44.5%	8.0%								
Total adjustments			25.8	72.6	98.4	106.6	205.0	139.8	246.4	344.9	96.5	101.5	198.0				274.1%	39.7%	101.1%							

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany
Life Science

€ million

	2022								2023								Change YoY																	
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY										
Net sales	2,445.4	2,647.8	5,093.2	2,680.7	7,773.9	2,606.4	5,287.1	10,380.3	2,486.8	2,353.5	4,840.3																	1.7%	-11.1%	-5.0%				
Cost of sales	-965.1	-1,052.3	-2,017.4	-1,070.5	-3,087.9	-1,192.1	-2,262.6	-4,280.0	-999.2	-1,078.2	-2,077.5																		3.5%	2.5%	3.0%			
thereof amortization of intangible assets	-13.5	-16.7	-30.2	-15.2	-45.4	-15.1	-30.2	-60.4	-13.3	-13.5	-26.8																		-1.0%	-19.4%	-11.1%			
Gross profit	1,480.4	1,595.5	3,075.8	1,610.2	4,686.0	1,414.4	3,024.5	6,100.4	1,487.5	1,275.3	2,762.8																		0.5%	-20.1%	-10.2%			
<i>in % of net sales</i>	60.5%	60.3%	60.4%	60.1%	60.3%	54.3%	57.2%	58.8%	59.8%	54.2%	57.1%																							
SG&A	-669.0	-731.6	-1,400.5	-785.3	-2,185.8	-707.4	-1,492.6	-2,893.2	-711.3	-720.8	-1,432.2																			6.3%	-1.5%	2.3%		
<i>in % of net sales</i>	27.4%	27.6%	27.5%	29.3%	28.1%	27.1%	28.2%	27.9%	28.6%	30.6%	29.6%																							
Marketing and selling expenses	-552.0	-608.8	-1,160.8	-633.9	-1,794.7	-605.4	-1,239.2	-2,400.1	-567.5	-566.3	-1,133.8																				2.8%	-7.0%	-2.3%	
thereof amortization of intangible assets (M&S)	-95.6	-103.6	-199.2	-107.5	-306.7	-107.7	-215.2	-414.4	-101.4	-100.4	-201.8																				6.1%	-3.1%	1.3%	
Administration expenses	-91.5	-102.8	-194.2	-112.0	-306.2	-93.4	-205.4	-399.7	-105.0	-102.8	-207.7																				14.8%	0.0%	7.0%	
Impairment losses and reversals (IFRS 9)	-1.7	-7.6	-9.3	1.7	-7.7	-0.9	0.8	-8.5	-1.1	-1.2	-2.3																				-37.1%	-83.9%	-75.3%	
Other operating expenses/income	-23.8	-12.3	-36.1	-41.1	-77.2	-7.7	-48.8	-84.9	-37.8	-50.6	-88.3																				58.4%	311.0%	144.4%	
Impairments**	-1.3	0.0	-1.3	0.0	-1.3	-23.2	-23.2	-24.5	0.0	-31.9	-31.9																				-100.0%	>1,000%	>1,000%	
Research and development costs	-88.1	-98.5	-186.7	-105.7	-292.3	-106.8	-212.5	-399.2	-103.8	-99.1	-203.0																					17.8%	0.6%	8.7%
<i>in % of net sales</i>	3.6%	3.7%	3.7%	3.9%	3.8%	4.1%	4.0%	3.8%	4.2%	4.2%	4.2%																							
thereof amortization of intangible assets (R&D)	-0.8	-0.8	-1.6	-0.8	-2.4	-0.7	-1.5	-3.1	-3.4	-2.0	-5.4																					327.5%	153.1%	240.3%
EBIT	723.3	765.4	1,488.6	719.2	2,207.9	600.2	1,319.4	2,808.0	672.4	455.3	1,127.7																							
<i>in % of net sales</i>	29.6%	28.9%	29.2%	26.8%	28.4%	23.0%	25.0%	27.1%	27.0%	19.3%	23.3%																							
Depreciation and amortization	198.3	209.9	408.2	216.6	624.9	244.9	461.5	869.7	211.7	243.1	454.8																					6.7%	15.8%	11.4%
EBITDA	921.6	975.3	1,896.9	935.9	2,832.7	845.0	1,780.9	3,677.8	884.0	698.5	1,582.5																							
<i>in % of net sales</i>	37.7%	36.8%	37.2%	34.9%	36.4%	32.4%	33.7%	35.4%	35.5%	29.7%	32.7%																							
EBITDA pre	927.1	1,005.7	1,932.8	976.4	2,909.2	850.3	1,826.8	3,759.6	900.6	711.9	1,612.5																							
<i>in % of net sales</i>	37.9%	38.0%	37.9%	36.4%	37.4%	32.6%	34.6%	36.2%	36.2%	30.2%	33.3%																							
Reconciliation to EBITDA pre																																		
EBITDA	921.6	975.3	1,896.9	935.9	2,832.7	845.0	1,780.9	3,677.8	884.0	698.5	1,582.5																							
Adjustments																																		
thereof: Cost of Sales	0.1	3.0	3.1	2.4	5.5	1.2	3.7	6.7	0.2	-0.1	0.1																							
thereof: Marketing and selling expenses	0.1	11.3	11.4	4.8	16.2	0.3	5.1	16.4	-1.2	0.3	-0.9																							
thereof: Administration expenses	7.2	9.0	16.3	10.2	26.4	-4.3	5.9	22.2	11.1	12.0	23.0																							
thereof: Other operating expenses/income	-1.9	7.0	5.0	23.1	28.2	8.4	31.5	36.5	6.4	0.5	6.9																							
thereof: Research and development	0.1	0.1	0.2	0.0	0.2	-0.3	-0.3	-0.1	0.0	0.7	0.8																							
Total	5.5	30.4	35.9	40.5	76.5	5.3	45.8	81.8	16.5	13.4	29.9																							
EBITDA pre	927.1	1,005.7	1,932.8	976.4	2,909.2	850.3	1,826.8	3,759.6	900.6	711.9	1,612.5																							

Due to rounding the sum of individual values may not add up to totals presented.

Detailed reconciliation - Life Science

€ million	2022								2023								Change YoY																															
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY																								
EBIT	723.3	765.4	1,488.6	719.2	2,207.9	600.2	1,319.4	2,808.0	672.4	455.3	1,127.7																-7.0%	-40.5%	-24.2%																			
Regular depreciation and amortization*	87.2	88.8	176.0	93.2	269.2	98.2	191.4	367.4	93.5	95.4	188.9																7.3%	7.4%	7.3%																			
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																n.m.	n.m.	n.m.																			
Amortization of purchased intangible assets	109.9	121.1	231.0	123.5	354.4	123.5	246.9	477.9	118.2	115.8	234.0																7.5%	-4.3%	1.3%																			
Impairments (net)**	1.3	0.0	1.3	0.0	1.3	23.2	23.2	24.5	0.0	31.9	31.9																-100.0%	>1.000%	>1.000%																			
Total depreciation and amortization	198.3	209.9	408.2	216.6	624.9	244.9	461.5	869.7	211.7	243.1	454.8																6.7%	15.8%	11.4%																			
EBITDA	921.6	975.3	1,896.9	935.9	2,832.7	845.0	1,780.9	3,677.8	884.0	698.5	1,582.5																-4.1%	-28.4%	-16.6%																			
Adjustments																																																
Acquisition costs	0.5	7.5	8.0	2.2	10.1	7.4	9.5	17.5	5.0	-0.3	4.8																882.2%	n.m.	-39.9%																			
Restructuring costs																																																
Restructuring costs	-3.1	13.1	10.0	28.3	38.2	2.3	30.6	40.6	0.4	1.8	2.2																n.m.	-85.9%	-77.5%																			
Total	-3.1	13.1	10.0	28.3	38.2	2.3	30.6	40.6	0.4	1.8	2.2																n.m.	-85.9%	-77.5%																			
Integration costs/IT costs																																																
Integration Cost	1.0	1.4	2.4	0.3	2.7	1.2	1.6	3.9	0.7	1.0	1.7																-25.5%	-29.0%	-27.5%																			
ERP/HR systems	7.1	8.6	15.6	9.8	25.5	-5.7	4.1	19.8	10.3	10.9	21.2																45.8%	26.9%	35.5%																			
Total	8.1	9.9	18.0	10.1	28.1	-4.4	5.7	23.7	11.1	11.8	22.9																37.0%	19.2%	27.2%																			
Gain (-)/ losses (+) on the divestment of businesses																																																
Costs related to former business activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																n.m.	n.m.	n.m.																			
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																n.m.	n.m.	n.m.																			
Other one-time costs																																																
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																n.m.	n.m.	n.m.																			
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																n.m.	n.m.	n.m.																			
Total adjustments	5.5	30.4	35.9	40.5	76.5	5.3	45.8	81.8	16.5	13.4	29.9																199.6%	-55.9%	-16.7%																			
EBITDA pre	927.1	1,005.7	1,932.8	976.4	2,909.2	850.3	1,826.8	3,759.6	900.6	711.9	1,612.5																-2.9%	-29.2%	-16.6%																			

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Healthcare

€ million

	2022								2023							Change YoY										
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY		
Net sales	1,795.0	1,924.2	3,719.1	2,089.3	5,808.5	2,030.3	4,119.6	7,838.7	1,905.5	2,049.5	3,955.0						6.2%	6.5%	6.3%							
Cost of sales	-460.7	-483.5	-944.3	-481.3	-1,425.5	-499.4	-980.7	-1,925.0	-446.6	-485.9	-932.6						-3.1%	0.5%	-1.2%							
thereof amortization of intangible assets	-1.2	-1.2	-2.4	-1.2	-3.5	-1.3	-2.5	-4.9	-1.2	-1.2	-2.3						-0.9%	-1.3%	-1.1%							
Gross profit	1,334.2	1,440.7	2,774.9	1,608.1	4,382.9	1,530.8	3,138.9	5,913.8	1,458.9	1,563.6	3,022.4						9.3%	8.5%	8.9%							
<i>in % of net sales</i>	74.3%	74.9%	74.6%	77.0%	75.5%	75.4%	76.2%	75.4%	76.6%	76.3%	76.4%															
SG&A	-482.9	-601.3	-1,084.2	-570.7	-1,654.9	-670.0	-1,240.7	-2,324.9	-543.9	-546.4	-1,090.2						12.6%	-9.1%	0.6%							
<i>in % of net sales</i>	26.9%	31.2%	29.2%	27.3%	28.5%	33.0%	30.1%	29.7%	28.5%	26.7%	27.6%															
Marketing and selling expenses	-375.6	-416.9	-792.5	-412.9	-1,205.4	-438.9	-851.8	-1,644.3	-380.6	-422.4	-803.0						1.3%	1.3%	1.3%							
thereof amortization of intangible assets (M&S)	-0.2	-0.2	-0.4	-0.1	-0.5	1.1	1.0	0.6	-0.3	-0.4	-0.7						29.8%	147.1%	76.3%							
Administration expenses	-71.2	-81.1	-152.3	-83.5	-235.8	-77.5	-161.0	-313.3	-75.5	-79.3	-154.8						6.0%	-2.2%	1.6%							
Impairment losses and reversals (IFRS 9)	-3.7	-0.5	-4.2	4.5	0.3	2.2	6.7	2.5	-1.0	-8.4	-9.4						-73.5%	>1.000%	124.4%							
Other operating expenses/income	-32.4	-102.9	-135.3	-78.7	-214.0	-155.8	-234.6	-369.8	-86.8	-36.2	-123.0						167.7%	-64.8%	-9.1%							
Impairments**	-0.8	-89.9	-90.8	-0.5	-91.2	-95.7	-96.2	-187.0	0.6	0.0	0.6						n.m.	n.m.	n.m.							
Research and development costs	-397.4	-400.7	-798.1	-431.4	-1,229.5	-464.8	-896.2	-1,694.3	-395.3	-401.5	-796.7						-0.5%	0.2%	-0.2%							
<i>in % of net sales</i>	22.1%	20.8%	21.5%	20.6%	21.2%	22.9%	21.8%	21.6%	20.7%	19.6%	20.1%															
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	-0.1	-0.1						n.m.	n.m.	n.m.							
EBIT	453.9	438.7	892.6	606.0	1,498.5	396.1	1,002.0	1,894.6	519.7	615.8	1,135.5						14.5%	40.4%	27.2%							
<i>in % of net sales</i>	25.3%	22.8%	24.0%	29.0%	25.8%	19.5%	24.3%	24.2%	27.3%	30.0%	28.7%															
Depreciation and amortization	71.7	164.0	235.7	76.7	312.4	177.9	254.6	490.2	72.9	76.2	149.1						1.7%	-53.5%	-36.7%							
EBITDA	525.6	602.7	1,128.3	682.6	1,810.9	573.9	1,256.6	2,384.8	592.6	692.0	1,284.6						12.8%	14.8%	13.9%							
<i>in % of net sales</i>	29.3%	31.3%	30.3%	32.7%	31.2%	28.3%	30.5%	30.4%	31.1%	33.8%	32.5%															
EBITDA pre	529.1	603.6	1,132.7	710.9	1,843.5	633.1	1,343.9	2,476.6	589.6	703.6	1,293.2						11.4%	16.6%	14.2%							
<i>in % of net sales</i>	29.5%	31.4%	30.5%	34.0%	31.7%	31.2%	32.6%	31.6%	30.9%	34.3%	32.7%															
Reconciliation to EBITDA pre																										
EBITDA	525.6	602.7	1,128.3	682.6	1,810.9	573.9	1,256.6	2,384.8	592.6	692.0	1,284.6						12.8%	14.8%	13.9%							
Adjustments																										
thereof: Cost of Sales	0.4	1.1	1.5	0.8	2.3	1.3	2.0	3.6	0.2	-1.7	-1.5						-52.0%	n.m.	n.m.							
thereof: Marketing and selling expenses	0.4	1.4	1.8	1.2	3.1	9.8	11.0	12.9	0.3	4.6	4.9						-24.4%	220.0%	165.6%							
thereof: Administration expenses	2.0	2.9	4.9	4.1	9.0	8.5	12.6	17.5	4.0	3.5	7.4						103.6%	18.8%	52.8%							
thereof: Other operating expenses/income	0.0	-10.1	-10.1	0.0	-10.1	-4.8	-4.8	-14.8	0.3	0.3	0.6						n.m.	n.m.	n.m.							
thereof: Research and development	0.7	5.5	6.3	22.1	28.4	44.3	66.4	72.7	-7.8	5.0	-2.8						n.m.	-9.3%	n.m.							
Total	3.5	0.9	4.4	28.2	32.6	59.1	87.3	91.8	-3.0	11.6	8.6						n.m.	>1.000%	93.5%							
EBITDA pre	529.1	603.6	1,132.7	710.9	1,843.5	633.1	1,343.9	2,476.6	589.6	703.6	1,293.2						11.4%	16.6%	14.2%							

Due to rounding the sum of individual values may not add up to totals presented.

Detailed reconciliation - Healthcare

€ million	2022								2023								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	453.9	438.7	892.6	606.0	1,498.5	396.1	1,002.0	1,894.6	519.7	615.8	1,135.5								14.5%	40.4%	27.2%			
Regular depreciation and amortization*	69.5	72.7	142.2	74.9	217.1	81.7	156.6	298.7	71.9	70.4	142.3								3.5%	-3.1%	0.1%			
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0	4.2	4.2								n.m.	n.m.	n.m.			
Amortization of purchased intangible assets	1.4	1.3	2.8	1.3	4.0	0.3	1.5	4.3	1.5	1.6	3.2								8.5%	20.9%	14.5%			
Impairments (net)**	0.8	89.9	90.8	0.5	91.2	95.7	96.2	187.0	-0.6	0.0	-0.6								n.m.	n.m.	n.m.			
Total depreciation and amortization	71.7	164.0	235.7	76.7	312.4	177.9	254.6	490.2	72.9	76.2	149.1								1.7%	-53.5%	-36.7%			
EBITDA	525.6	602.7	1,128.3	682.6	1,810.9	573.9	1,256.6	2,384.8	592.6	692.0	1,284.6								12.8%	14.8%	13.9%			
Adjustments																								
Acquisition costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								n.m.	n.m.	n.m.			
Restructuring costs																								
Restructuring costs	1.9	8.3	10.2	24.5	34.7	56.3	80.7	91.0	-7.3	12.0	4.7								n.m.	44.8%	-54.0%			
Total	1.9	8.3	10.2	24.5	34.7	56.3	80.7	91.0	-7.3	12.0	4.7								n.m.	44.8%	-54.0%			
Integration costs/IT costs																								
Integration Cost	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								n.m.	n.m.	n.m.			
ERP/HR systems	1.6	2.7	4.3	3.7	8.1	7.6	11.3	15.6	4.0	3.5	7.4								149.9%	27.4%	72.4%			
Total	1.6	2.7	4.3	3.7	8.1	7.6	11.3	15.6	4.0	3.5	7.4								149.9%	27.4%	72.4%			
Gain (-)/ losses (+) on the divestment of businesses																								
Sale of Kuvan and Biosimilars	0.0	-9.8	-9.8	0.0	-9.8	-4.7	-4.7	-14.4	0.0	-7.6	-7.6								>1.000%	-22.4%	-22.2%			
Sale of Consumer Health	0.0	-0.3	-0.4	0.0	-0.3	-0.4	-0.4	-0.7	0.0	4.3	4.3								n.m.	n.m.	n.m.			
Sale of Allergopharma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								n.m.	n.m.	n.m.			
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								n.m.	n.m.	n.m.			
Total	0.0	-10.1	-10.1	0.0	-10.1	-4.7	-4.7	-14.8	0.3	-3.9	-3.6								n.m.	-61.5%	-64.5%			
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								-100.0%	n.m.	-100.0%			
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								-100.0%	n.m.	-100.0%			
Total adjustments	3.5	0.9	4.4	28.2	32.6	59.1	87.3	91.8	-3.0	11.6	8.6								n.m.	>1.000%	93.5%			
EBITDA pre	529.1	603.6	1,132.7	710.9	1,843.5	633.1	1,343.9	2,476.6	589.6	703.6	1,293.2								11.4%	16.6%	14.2%			

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Electronics

€ million

	2022								2023								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	957.4	996.4	1,953.9	1,035.7	2,989.5	1,023.7	2,059.3	4,013.2	900.7	899.3	1,800.0						-5.9%	-9.7%	-7.9%					
Cost of sales	-560.0	-570.8	-1,130.9	-591.0	-1,721.8	-591.8	-1,182.8	-2,313.7	-525.8	-572.2	-1,097.9						-6.1%	0.2%	-2.9%					
thereof amortization of intangible assets	-35.7	-35.4	-71.0	-35.9	-107.0	-34.9	-70.8	-141.9	-33.6	-31.5	-65.2						-5.7%	-10.8%	-8.3%					
Gross profit	397.4	425.6	823.0	444.7	1,267.7	431.8	876.5	1,699.5	374.9	327.2	702.1						-5.7%	-23.1%	-14.7%					
<i>in % of net sales</i>	41.5%	42.7%	42.1%	42.9%	42.4%	42.2%	42.6%	42.3%	41.6%	36.4%	39.0%													
SG&A	-176.9	-204.3	-381.2	-222.4	-603.5	-215.2	-437.6	-818.7	-215.1	-142.5	-357.7						21.6%	-30.2%	-6.2%					
<i>in % of net sales</i>	18.5%	20.5%	19.5%	21.5%	20.2%	21.0%	21.2%	20.4%	23.9%	15.8%	19.9%													
Marketing and selling expenses	-155.7	-163.1	-318.8	-172.6	-491.4	-171.1	-343.6	-662.4	-158.2	-147.6	-305.8						1.6%	-9.5%	-4.1%					
thereof amortization of intangible assets (M&S)	-48.9	-50.0	-98.9	-52.3	-151.2	-51.4	-103.7	-202.6	-49.5	-48.2	-97.6						1.2%	-3.7%	-1.2%					
Administration expenses	-28.2	-32.9	-61.1	-33.1	-94.2	-33.6	-66.7	-127.9	-33.0	-35.1	-68.1						16.9%	6.5%	11.3%					
Impairment losses and reversals (IFRS 9)	0.2	-0.2	0.0	-0.2	-0.2	-0.1	-0.4	-0.3	-0.1	-0.1	-0.2						n.m.	-70.2%	n.m.					
Other operating expenses/income	6.8	-8.1	-1.2	-16.5	-17.7	-10.4	-26.9	-28.1	-23.8	40.2	16.4						n.m.	n.m.	n.m.					
Impairments**	-0.3	0.0	-0.3	-10.4	-10.7	-9.4	-19.8	-20.1	-10.3	-5.0	-15.3						>1.000%	>1.000%	>1.000%					
Research and development costs	-75.3	-72.8	-148.2	-78.4	-226.6	-81.7	-160.1	-308.3	-74.1	-74.5	-148.7						-1.6%	2.3%	0.3%					
<i>in % of net sales</i>	7.9%	7.3%	7.6%	7.6%	7.6%	8.0%	7.8%	7.7%	8.2%	8.3%	8.3%													
thereof amortization of intangible assets (R&D)	-0.9	-0.9	-1.8	-0.8	-2.6	-1.0	-1.8	-3.6	-1.0	-0.9	-1.9						10.8%	2.3%	6.4%					
EBIT	145.2	148.5	293.7	143.9	437.5	134.9	278.8	572.5	85.7	110.1	195.8						-41.0%	-25.8%	-33.3%					
<i>in % of net sales</i>	15.2%	14.9%	15.0%	13.9%	14.6%	13.2%	13.5%	14.3%	9.5%	12.2%	10.9%													
Depreciation and amortization	133.6	133.6	267.1	150.2	417.3	147.7	297.9	565.1	142.6	134.7	277.3						6.7%	0.9%	3.8%					
EBITDA	278.8	282.0	560.8	294.1	854.9	282.7	576.8	1,137.6	228.2	244.8	473.1						-18.1%	-13.2%	-15.6%					
<i>in % of net sales</i>	29.1%	28.3%	28.7%	28.4%	28.6%	27.6%	28.0%	28.3%	25.3%	27.2%	26.3%													
EBITDA pre	289.3	293.1	582.4	301.6	884.0	308.2	609.8	1,192.2	237.3	261.7	499.1						-18.0%	-10.7%	-14.3%					
<i>in % of net sales</i>	30.2%	29.4%	29.8%	29.1%	29.6%	30.1%	29.6%	29.7%	26.4%	29.1%	27.7%													
Reconciliation to EBITDA pre																								
EBITDA	278.8	282.0	560.8	294.1	854.9	282.7	576.8	1,137.6	228.2	244.8	473.1						-18.1%	-13.2%	-15.6%					
Adjustments																								
thereof: Cost of Sales	1.1	3.7	4.8	2.8	7.6	13.7	16.5	21.3	2.0	5.9	8.0						86.7%	61.1%	66.9%					
thereof: Marketing and selling expenses	0.1	1.3	1.4	0.4	1.8	1.2	1.6	2.9	0.0	0.5	0.5						-89.2%	-63.0%	-64.2%					
thereof: Administration expenses	0.3	1.9	2.2	1.2	3.4	4.9	6.1	8.3	2.0	3.6	5.7						553.2%	92.8%	157.7%					
thereof: Other operating expenses/income	8.9	3.5	12.4	3.1	15.5	4.7	7.8	20.1	5.1	6.4	11.5						-42.2%	82.3%	-7.0%					
thereof: Research and development	0.2	0.7	0.9	0.0	0.9	1.1	1.0	2.0	-0.1	0.5	0.4						n.m.	-33.0%	-58.3%					
Total	10.6	11.1	21.6	7.5	29.1	25.5	33.0	54.6	9.1	16.9	26.0						-13.7%	52.8%	20.3%					
EBITDA pre	289.3	293.1	582.4	301.6	884.0	308.2	609.8	1,192.2	237.3	261.7	499.1						-18.0%	-10.7%	-14.3%					

Due to rounding the sum of individual values may not add up to totals presented.

Detailed reconciliation - Electronics

€ million	2022								2023								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	145.2	148.5	293.7	143.9	437.5	134.9	278.8	572.5	85.7	110.1	195.8													
Regular depreciation and amortization*	47.9	47.3	95.2	50.7	145.9	51.0	101.8	197.0	48.2	49.1	97.3						0.6%	-25.8%	-33.3%	0.6%	3.9%	2.2%		
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.					
Amortization of purchased intangible assets	85.4	86.3	171.7	89.0	260.7	87.3	176.3	348.0	84.1	80.6	164.7						-1.6%	-6.5%	-4.1%					
Impairments (net)**	0.3	0.0	0.3	10.4	10.7	9.4	19.8	20.1	10.3	5.0	15.3						>1.000%	>1.000%	>1.000%					
Total depreciation and amortization	133.6	133.6	267.1	150.2	417.3	147.7	297.9	565.1	142.6	134.7	277.3						6.7%	0.9%	3.8%					
EBITDA	278.8	282.0	560.8	294.1	854.9	282.7	576.8	1,137.6	228.2	244.8	473.1						-18.1%	-13.2%	-15.6%					
Adjustments																								
Acquisition costs	1.0	1.1	2.1	5.1	7.3	4.2	9.3	11.4	4.2	5.1	9.2						302.6%	354.8%	329.6%					
Restructuring costs																								
Restructuring costs	4.7	8.5	13.1	3.4	16.6	14.0	17.4	30.6	2.2	6.9	9.1						-53.7%	-18.4%	-30.9%					
Total	4.7	8.5	13.1	3.4	16.6	14.0	17.4	30.6	2.2	6.9	9.1						-53.7%	-18.4%	-30.9%					
Integration costs/IT costs																								
Integration Cost	3.9	0.3	4.3	-2.4	1.8	2.9	0.5	4.8	1.1	1.0	2.1						-71.4%	224.3%	-49.5%					
ERP/HR systems	0.9	1.1	2.1	1.4	3.5	4.4	5.8	7.9	1.7	3.9	5.6						79.2%	238.8%	167.4%					
Total	4.9	1.5	6.3	-1.0	5.3	7.3	6.3	12.6	2.8	4.9	7.7						-42.6%	235.7%	21.6%					
Gain (-)/ losses (+) on the divestment of businesses																								
Costs related to former business activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.					
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.					
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.					
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.					
Total adjustments	10.6	11.1	21.6	7.5	29.1	25.5	33.0	54.6	9.1	16.9	26.0						-13.7%	52.8%	20.3%					
EBITDA pre	289.3	293.1	582.4	301.6	884.0	308.2	609.8	1,192.2	237.3	261.7	499.1						-18.0%	-10.7%	-14.3%					

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany
Corporate and Other

€ million

	2022								2023								Change YoY											
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY				
Net sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																	
Cost of sales	-1.2	-2.0	-3.2	-4.7	-7.9	-0.8	-5.5	-8.7	-0.9	-2.6	-3.5																	
thereof amortization of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																	
Gross profit	-1.2	-2.0	-3.2	-4.7	-7.9	-0.8	-5.5	-8.7	-0.9	-2.6	-3.5																	
SG&A	-123.0	-146.0	-269.0	-204.0	-473.1	-200.4	-404.5	-673.5	-217.8	-183.9	-401.7																	
Marketing and selling expenses	-4.0	-4.7	-8.7	-4.1	-12.8	5.9	1.8	-7.0	-2.8	-3.1	-5.9																	
thereof amortization of intangible assets (M&S)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																	
Administration expenses	-96.3	-113.8	-210.1	-99.3	-309.3	-156.3	-255.6	-465.6	-144.4	-127.9	-272.3																	
Impairment losses and reversals (IFRS 9)	0.2	-0.3	-0.1	0.3	0.2	0.7	1.0	0.9	0.0	0.0	0.0																	
Other operating expenses/income	-23.0	-27.2	-50.2	-100.9	-151.1	-50.7	-151.6	-201.8	-70.6	-52.9	-123.5																	
Impairments**	-0.3	0.0	-0.3	0.0	-0.3	-0.1	-0.1	-0.4	0.0	0.0	0.0																	
Research and development costs	-24.7	-27.5	-52.2	-26.2	-78.4	-40.4	-66.6	-118.8	-24.1	-25.3	-49.4																	
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																	
EBIT	-148.9	-175.5	-324.4	-234.9	-559.3	-241.6	-476.5	-800.9	-242.8	-211.7	-454.5																	
Depreciation and amortization	25.9	24.9	50.8	26.2	77.0	28.0	54.2	105.1	28.4	28.2	56.6																	
EBITDA	-123.0	-150.6	-273.6	-208.7	-482.3	-213.6	-422.3	-695.9	-214.4	-183.5	-397.9																	
EBITDA pre	-116.8	-120.3	-237.1	-178.4	-415.5	-163.7	-342.0	-579.2	-140.5	-123.9	-264.5																	
Reconciliation to EBITDA pre																												
EBITDA	-123.0	-150.6	-273.6	-208.7	-482.3	-213.6	-422.3	-695.9	-214.4	-183.5	-397.9																	
Adjustments																												
thereof: Cost of Sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.6																	
thereof: Marketing and selling expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																	
thereof: Administration expenses	10.2	15.8	26.0	15.9	41.9	25.2	41.1	67.1	54.6	22.8	77.5																	
thereof: Other operating expenses/income	-3.9	14.4	10.4	14.5	24.9	24.7	39.2	49.6	19.0	35.0	54.0																	
thereof: Research and development	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.3																	
Total	6.2	30.2	36.4	30.3	66.8	49.9	80.2	116.7	73.9	59.6	133.5																	
EBITDA pre	-116.8	-120.3	-237.1	-178.4	-415.5	-163.7	-342.0	-579.2	-140.5	-123.9	-264.5																	

Due to rounding the sum of individual values may not add up to totals presented.

Detailed reconciliation - Corporate and Others

€ million	2022								2023								Change YoY											
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY				
EBIT	-148.9	-175.5	-324.4	-234.9	-559.3	-241.6	-476.5	-800.9	-242.8	-211.7	-454.5								63.0%	20.7%	40.1%							
Regular depreciation and amortization*	25.7	24.9	50.6	26.2	76.7	28.0	54.1	104.7	28.4	28.2	56.6								10.7%	13.3%	11.9%							
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0																	
Amortization of purchased intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								4.6%	-2.2%	1.1%							
Impairments (net)**	0.3	0.0	0.3	0.0	0.3	0.1	0.1	0.4	0.0	0.0	0.0								-100.0%	-100.0%	-100.0%							
Total depreciation and amortization	25.9	24.9	50.8	26.2	77.0	28.0	54.2	105.1	28.4	28.2	56.6								9.5%	13.2%	11.4%							
EBITDA	-123.0	-150.6	-273.6	-208.7	-482.3	-213.6	-422.3	-695.9	-214.4	-183.5	-397.9								74.3%	21.9%	45.5%							
Adjustments																												
Acquisition costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								n.m.	n.m.	n.m.							
Restructuring costs																												
Restructuring costs	4.8	7.9	12.8	7.0	19.8	16.5	23.5	36.3	49.0	18.5	67.6								>1.000%	133.6%	429.4%							
Total	4.8	7.9	12.8	7.0	19.8	16.5	23.5	36.3	49.0	18.5	67.6								>1.000%	133.6%	429.4%							
IT project costs																												
Integration Cost	0.0	0.5	0.5	0.0	0.5	0.0	0.1	0.6	0.0	0.1	0.1																	
ERP/HR systems	5.4	9.6	15.0	9.8	24.8	10.2	20.0	35.0	5.6	6.8	12.4								3.6%	-29.0%	-17.3%							
Total	5.4	10.1	15.5	9.9	25.4	10.2	20.1	35.6	5.6	6.9	12.5								4.2%	-31.8%	-19.2%							
Gain (-)/ losses (+) on the divestment of businesses																												
Costs related to former business activities	-10.3	-11.5	-21.8	-4.1	-25.9	3.2	-0.9	-22.7	0.0	21.0	21.0								-100.0%	n.m.	n.m.							
Total	-10.3	-11.5	-21.8	-4.1	-25.9	3.2	-0.9	-22.7	0.0	21.0	21.0								-100.0%	n.m.	n.m.							
Other one-time costs																												
Others	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2	13.2	32.4								208.4%	-44.5%	8.0%							
Total	6.2	23.8	30.0	17.5	47.5	20.0	37.5	67.5	19.2	13.2	32.4								208.4%	-44.5%	8.0%							
Total adjustments	6.2	30.2	36.4	30.3	66.8	49.9	80.2	116.7	73.9	59.6	133.5								>1.000%	97.1%	266.3%							
EBITDA pre	-116.8	-120.3	-237.1	-178.4	-415.5	-163.7	-342.0	-579.2	-140.5	-123.9	-264.5								20.3%	3.0%	11.5%							

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Group € million	2022								2023							Change YoY								
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Financial result	-34.3	-55.1	-89.4	-47.0	-136.4	-50.5	-97.5	-186.9	-22.7	-75.7	-98.4						-33.9%	37.4%	10.0%					
Interest result	-23.0	-48.9	-71.9	-22.3	-94.2	-30.0	-52.4	-124.3	-27.4	-48.7	-76.1						19.0%	-0.3%	5.9%					
Interest income	25.0	7.4	32.4	28.6	60.9	8.4	37.0	69.4	20.6	36.7	57.3						-17.7%	397.6%	76.9%					
Interest expenses	-48.0	-56.2	-104.3	-50.9	-155.2	-38.5	-89.4	-193.7	-48.0	-85.4	-133.4						-0.1%	51.9%	27.9%					
Result from financial investments	-3.0	-3.7	-6.8	-2.2	-8.9	6.9	4.8	-2.0	13.4	7.4	20.8						n.m.	n.m.	n.m.					
Currency difference - financing	-2.5	-7.1	-9.6	-6.4	-16.0	-10.4	-16.9	-26.4	-1.4	-4.8	-6.3						-41.3%	-32.1%	-34.5%					
Interest quota - pensions and other provisions	-5.9	4.7	-1.1	-16.1	-17.2	-16.9	-33.0	-34.1	-7.3	-29.5	-36.8						24.0%	n.m.	>1.000%					
Others	0.1	-0.1	0.0	0.0	0.0	0.0	0.0	-0.1	0.0	0.0	0.0						n.m.	-100.0%	-100.0%					

Cash Flow Statement Merck KGaA, Darmstadt, Germany
Group

€ million

	2022								2023								Change YoY								
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	
Profit after tax	883.7	870.2	1,754.0	926.0	2,679.9	659.3	1,585.3	3,339.3	799.7	706.1	1,505.8						-9.5%	-18.9%	-14.1%						
Depreciation/amortization/impairment losses/reversals of impairment losses of tangible assets	429.6	532.3	961.9	469.7	1,431.6	598.5	1,068.2	2,030.1	455.5	482.3	937.8						6.0%	-9.4%	-2.5%						
of intangible assets	206.7	208.8	415.4	219.3	634.7	252.7	472.0	887.4	216.6	216.7	433.3						4.8%	3.8%	4.3%						
Changes in working capital	222.9	323.6	546.5	250.4	796.8	345.8	596.2	1,142.7	238.9	265.6	504.5						7.2%	-17.9%	-7.7%						
Changes in inventories	-322.3	-324.9	-647.2	-180.7	-827.9	-86.8	-269.5	-916.7	-223.9	-52.9	-276.8						-30.5%	-83.7%	-57.2%						
Changes in trade accounts receivable	-186.4	-200.7	-387.1	-248.6	-635.7	31.5	-217.2	-604.2	-322.5	-106.3	-428.9						73.0%	-47.0%	10.8%						
Changes in trade accounts payable/ refund liability:	-343.1	-193.8	-536.9	149.1	-387.8	-25.3	123.8	-413.1	-116.5	14.7	-101.8						-66.0%	n.m.	-81.0%						
Changes in provisions ¹	207.2	69.6	276.8	-81.2	195.6	-95.0	-176.1	100.7	215.1	38.8	253.9						3.8%	-44.3%	-8.3%						
Changes in other assets and liabilities ¹	106.6	-92.5	14.1	111.2	125.3	153.7	264.9	279.0	-8.0	53.3	45.3						n.m.	n.m.	222.4%						
Neutralization of gain/loss on disposal of fixed assets and other disposal	-233.6	-132.9	-366.6	234.5	-132.1	-313.2	-78.7	-445.3	-187.0	-421.0	-608.0						-20.0%	216.8%	65.9%						
Other non-cash income and expenses	-26.8	-12.1	-38.9	-3.7	-42.5	-5.8	-9.4	-48.3	-0.2	-145.5	-145.7						-99.3%	>1,000%	274.9%						
Other non-cash income and expenses	2.9	12.2	15.1	-5.3	9.8	11.2	5.9	21.0	16.5	0.1	16.7						480.4%	-98.8%	10.9%						
Operating Cash Flow	840.0	852.4	1,692.4	1,551.7	3,244.1	1,015.0	2,566.8	4,259.1	852.7	622.4	1,475.2						1.5%	-27.0%	-12.8%						
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.						
Payments for investments in intangible asset:	-67.9	-52.0	-119.9	-89.2	-209.2	-66.3	-155.6	-275.5	-79.0	-30.9	-109.9						16.3%	-40.6%	-8.3%						
Payments from the disposal of intangible asset:	20.6	4.8	25.4	10.1	35.4	2.3	12.4	37.7	4.4	125.8	130.2						-78.8%	>1,000%	413.3%						
Payments for investments in property, plant and equipment	-430.5	-246.0	-676.5	-388.5	-1,065.0	-466.4	-854.9	-1,531.4	-572.3	-295.6	-867.9						32.9%	20.2%	28.3%						
Payments from the disposal of property, plant and equipment	17.1	-7.2	9.9	3.9	13.8	7.1	11.0	20.9	10.1	3.3	13.4						-40.7%	n.m.	35.0%						
Payments for acquisitions less acquired cash and cash equivalents (net)	-694.8	0.0	-694.8	-0.7	-695.5	-158.2	-159.0	-853.8	0.1	0.1	0.1						n.m.	n.m.	n.m.						
Payments from other divestments	3.7	0.5	4.2	0.1	4.3	-0.1	0.1	4.2	-0.1	-0.2	-0.2						n.m.	n.m.	n.m.						
Payments for investments in financial asset:	-24.4	-23.2	-47.6	-168.7	-216.3	-148.1	-316.8	-364.4	-21.9	-12.2	-34.1						-10.3%	-47.5%	-28.4%						
Proceeds from the disposal of other financial asset	88.8	37.5	124.3	11.2	135.6	83.9	95.2	219.5	224.5	42.9	267.5						158.5%	14.5%	115.1%						
Payments for the acquisition of non-financial asset	-100.0	-500.0	-600.0	0.0	-600.0	0.0	0.0	-600.0	-897.0	-1,207.2	-2,104.2						797.0%	141.4%	250.7%						
Proceeds from the disposal of non-financial asset:	100.0	0.0	100.0	0.0	100.0	500.0	500.0	600.0	100.0	1,514.2	1,614.2						0.0%	n.m.	>1,000%						
Investing Cash Flow	-1,089.4	-785.7	-1,875.1	-621.9	-2,496.9	-245.8	-867.6	-2,742.7	-1,231.1	140.2	-1,091.0						13.0%	n.m.	-41.8%						
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.						
Dividend payments to Merck KGaA shareholders	0.0	-239.1	-239.1	0.0	-239.1	0.0	0.0	-239.1	0.0	-284.3	-284.3						n.m.	18.9%	18.9%						
Dividend payments to non-controlling interests	-9.6	-1.6	-11.2	0.0	-11.2	-0.3	-0.3	-11.5	0.0	-10.3	-10.3						-100.0%	546.4%	-8.0%						
Profit withdrawal by E.Merck KG	-90.5	-625.6	-716.1	0.0	-716.1	0.0	0.0	-716.1	-90.4	-777.6	-868.0						-0.2%	24.3%	21.2%						
Changes in financial liabilities to E. Merck KG and E. Merck Beteiligungen KK	-406.0	976.7	570.7	-104.7	466.0	-442.7	-547.4	23.3	-0.8	697.8	697.1						-99.8%	-28.5%	22.1%						
Other changes in net equity	0.3	-0.3	0.0	-0.1	-0.2	0.2	0.1	0.1	0.0	0.0	0.0						n.m.	n.m.	n.m.						
Changes in current and non-current financial liability:	190.9	57.1	247.9	-804.4	-556.4	-55.3	-859.7	-611.7	215.6	-206.0	9.7						13.0%	n.m.	-96.1%						
Other changes from financing activities	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0						-61.2%	n.m.	n.m.						
Financing Cash Flow	-315.0	167.2	-147.8	-909.1	-1,056.9	-498.1	-1,407.2	-1,555.0	124.5	-580.4	-455.9						n.m.	n.m.	208.5%						
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.						
Changes in cash and cash equivalents	-564.3	233.9	-330.5	20.8	-309.7	271.1	291.9	-38.6	-254.0	182.2	-71.7						-55.0%	-22.1%	-78.3%						
Changes in cash and cash equivalents due to currency translation	3.5	7.3	10.8	4.1	14.9	-21.7	-17.7	-6.9	-15.7	-5.3	-21.1						n.m.	n.m.	n.m.						
Cash and cash equivalents as of January 1s	1,899.3	0.0	1,899.3	0.0	1,899.3	0.0	1,899.3	1,853.8	1,853.8	0.0	1,853.8						-2.4%	n.m.	-2.4%						
Cash and cash equivalents	1,338.5	241.1	1,579.6	24.9	1,604.4	249.4	274.2	1,853.8	1,584.1	176.9	1,761.0						18.4%	-26.6%	11.5%						
Changes in cash and cash equivalents due to change in scope of consolidator	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0						n.m.	n.m.	n.m.						

¹ As of January 1, 2023, the tranche of the Group Long-Term Incentive Plan to be paid out in the months following the balance sheet date is disclosed under other current non-financial liabilities and no longer under current provisions for employee benefits. For better comparability, the previous year's figures have been adjusted.
Due to rounding the sum of individual values may not add up to totals presented.

Balance Sheet Merck KGaA, Darmstadt, Germany
Group

€ million

	2022				2023				Shares of Totals				Shares of Totals			
	31. Mrz	30. Jun	30. Sep	31. Dez	31. Mrz	30. Jun	30. Sep	31. Dez	31. Mrz	30. Jun	30. Sep	31. Dez	31. Mrz	30. Jun	30. Sep	31. Dez
Non-current assets	35,149.3	36,301.2	37,990.0	36,334.3	35,686.3	35,763.3			76.0%	74.5%	74.6%	74.9%	73.4%	73.3%		
Goodwill ¹	17,760.8	18,573.4	19,534.1	18,388.9	18,077.4	18,102.2			38.4%	38.1%	38.4%	37.9%	37.2%	37.1%		
Other intangible assets ¹	7,549.5	7,861.8	8,079.8	7,335.4	6,953.8	6,765.2			16.3%	16.1%	15.9%	15.1%	14.3%	13.9%		
Property, plant and equipment ¹	7,302.9	7,573.4	7,945.6	8,204.3	8,217.9	8,393.4			15.8%	15.5%	15.6%	16.9%	16.9%	17.2%		
Investments accounted for using the equity method	2.8	3.0	3.1	2.9	2.9	2.9			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
Other non-current receivables	24.5	25.7	28.1	27.1	23.9	23.2			0.1%	0.1%	0.1%	0.1%	0.0%	0.0%		
Other non-current financial assets	902.3	901.9	961.7	957.1	958.9	1,040.9			2.0%	1.9%	1.9%	2.0%	2.0%	2.1%		
Other non-current non-financial assets	104.8	99.5	104.1	99.1	99.6	88.1			0.2%	0.2%	0.2%	0.2%	0.2%	0.2%		
Non-current income tax receivables	9.8	9.7	9.4	9.8	9.3	9.2			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
Deferred tax assets	1,492.0	1,252.9	1,324.0	1,309.6	1,342.5	1,338.2			3.2%	2.6%	2.6%	2.7%	2.8%	2.7%		
Current assets	11,085.3	12,415.9	12,943.1	12,200.9	12,950.7	13,018.7			24.0%	25.5%	25.4%	25.1%	26.6%	26.7%		
Inventories	4,142.8	4,473.7	4,859.9	4,632.1	4,889.6	4,995.8			9.0%	9.2%	9.5%	9.5%	10.1%	10.2%		
Trade and other current receivables	4,138.4	4,413.7	4,346.3	4,113.6	4,269.8	4,209.8			9.0%	9.1%	8.5%	8.5%	8.8%	8.6%		
Contract assets	207.0	156.1	137.2	128.4	132.6	126.5			0.4%	0.3%	0.3%	0.3%	0.3%	0.3%		
Other current financial assets	105.9	133.5	347.1	321.3	136.8	166.3			0.2%	0.3%	0.7%	0.7%	0.3%	0.3%		
Other current non-financial assets	792.8	1,362.5	1,335.0	705.4	1,515.8	1,250.0			1.7%	2.8%	2.6%	1.5%	3.1%	2.6%		
Current income tax receivables	359.9	297.0	313.2	446.3	421.9	509.2			0.8%	0.6%	0.6%	0.9%	0.9%	1.0%		
Cash and cash equivalents	1,338.5	1,579.6	1,604.4	1,853.8	1,584.1	1,761.0			2.9%	3.2%	3.2%	3.8%	3.3%	3.6%		
Assets held for sale	0.0	0.0	0.0	0.0	0.0	0.0			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
Total assets	46,234.6	48,717.2	50,933.1	48,535.2	48,637.0	48,781.9			100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		
Total equity	22,990.1	26,028.7	28,337.0	26,005.42	26,230.0	26,771.9			49.7%	53.4%	55.6%	53.6%	53.9%	54.9%		
Equity capital	565.2	565.2	565.2	565.2	565.2	565.2			1.2%	1.2%	1.1%	1.2%	1.2%	1.2%		
Capital reserves	3,813.7	3,813.7	3,813.7	3,813.73	3,813.7	3,813.7			8.2%	7.8%	7.5%	7.9%	7.8%	7.8%		
Retained earnings	16,450.0	18,014.6	18,825.1	18,462.87	19,250.0	19,760.5			35.6%	37.0%	37.0%	38.0%	39.6%	40.5%		
Gain/losses recognized in equity	2,090.5	3,561.4	5,056.3	3,085.59	2,520.3	2,561.2			4.5%	7.3%	9.9%	6.4%	5.2%	5.3%		
Non-controlling interest	70.7	73.7	76.7	77.99	80.7	71.3			0.2%	0.2%	0.2%	0.2%	0.2%	0.1%		
Non-current liabilities	13,037.5	12,970.7	13,184.4	13,015.5	12,850.8	13,163.9			28.2%	26.6%	25.9%	26.8%	26.4%	27.0%		
Non-current provisions for employee benefits	2,879.1	1,666.1	1,954.9	2,030.0	1,965.3	1,994.5			6.2%	3.4%	3.8%	4.2%	4.0%	4.1%		
Other non-current provisions	279.1	265.2	300.3	299.4	307.0	294.1			0.6%	0.5%	0.6%	0.6%	0.6%	0.6%		
Non-current financial debt	8,285.8	9,385.4	9,265.6	9,200.4	9,159.3	9,495.4			17.9%	19.3%	18.2%	19.0%	18.8%	19.5%		
Other non-current financial liabilities ²	143.2	148.7	150.2	141.4	142.4	141.3			0.3%	0.3%	0.3%	0.3%	0.3%	0.3%		
Other non-current non-financial liabilities ²	20.4	21.8	23.1	19.4	19.3	19.0			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
Non-current income tax liabilities	40.7	41.3	40.9	38.1	38.0	37.5			0.1%	0.1%	0.1%	0.1%	0.1%	0.1%		
Deferred tax liabilities ¹	1,389.2	1,442.1	1,449.4	1,286.8	1,219.4	1,182.1			3.0%	3.0%	2.8%	2.7%	2.5%	2.4%		
Current liabilities	10,206.9	9,717.8	9,411.8	9,514.3	9,556.2	8,846.1			22.1%	19.9%	18.5%	19.6%	19.6%	18.1%		
Current provisions for employee benefits ³	96.1	181.8	207.4	80.6	131.6	105.9			0.2%	0.4%	0.4%	0.2%	0.3%	0.2%		
Other current provisions	372.0	341.5	355.0	372.4	378.8	448.1			0.8%	0.7%	0.7%	0.8%	0.8%	0.9%		
Current financial debt	2,344.9	2,417.7	1,784.5	1,227.9	1,484.9	1,690.1			5.1%	5.0%	3.5%	2.5%	3.1%	3.5%		
Other current financial liabilities ²	930.9	419.3	471.0	1,153.2	1,017.3	259.1			2.0%	0.9%	0.9%	2.4%	2.1%	0.5%		
Trade and other current payables ¹	2,356.3	2,456.3	2,445.1	2,498.7	2,326.1	2,402.7			5.1%	5.0%	4.8%	5.1%	4.8%	4.9%		
Refund liabilities	873.2	972.1	968.1	912.3	947.1	963.1			1.9%	2.0%	1.9%	1.9%	1.9%	2.0%		
Current income tax liabilities	1,465.8	1,430.0	1,520.2	1,483.4	1,461.4	1,487.8			3.2%	2.9%	3.0%	3.1%	3.0%	3.0%		
Other current non-financial liabilities ^{2,3}	1,767.8	1,499.0	1,660.5	1,785.8	1,809.1	1,489.4			3.8%	3.1%	3.3%	3.7%	3.7%	3.1%		
Liabilities included in disposal groups classified as held for sale	0.0	0.0	0.0	0.0	0.0	0.0			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
Total liabilities and stockholders' equity	46,234.6	48,717.2	50,933.1	48,535.2	48,637.0	48,781.9			100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		

	2022				2023				Shares of Totals				Shares of Totals			
	31. Mrz	30. Jun	30. Sep	31. Dez	31. Mrz	30. Jun	30. Sep	31. Dez	31. Mrz	30. Jun	30. Sep	31. Dez	31. Mrz	30. Jun	30. Sep	31. Dez
Financial debt	10,630.7	11,803.1	11,050.0	10,428.3	10,644.2	11,185.5			23.0%	24.2%	21.7%	21.5%	21.9%	22.9%		
Net financial debt	9,228.4	10,165.2	9,214.6	8,327.6	8,991.9	9,354.9			20.0%	20.9%	18.1%	17.2%	18.5%	19.2%		
Additions to Property, plant and equipment (excl. Leasing) ⁴	209.1	488.0	858.3	1,526.9	297.9	669.6			n.m.	n.m.	n.m.	n.m.	n.m.	n.m.		

Due to rounding the sum of individual values may not add up to totals presented.

¹ Previous-year figures have been adjusted owing to the finalization of the purchase price allocation in connection with the acquisitions of the chemical business of Mecaro Co. Ltd., Korea, trading as M Chemicals Inc., Korea, as well as Erbi Biosystems Inc., USA.

² As of January 1, 2023, wage- and salary-related liabilities are disclosed under other non-financial liabilities instead of under other financial liabilities as in the past.

For better comparability, the previous year's figures have been adjusted.

³ As of January 1, 2023, the tranche of the Group Long-Term Incentive Plan to be paid out in the months following the balance sheet date is disclosed under other current non-financial liabilities and no longer under current provisions for employee benefits. For better comparability, the previous year's figures have been adjusted.

⁴ Figures are year-to-date figures from January 1st until stated end date.